Delivery Order SPE2DB22D1202-SPE2DB25FUPM8

Award Date 1/14/25
Potential Completion Date 1/15/25
Potential Value $3.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $3,710.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $8,832.09, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 20 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $12,170.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract has a completion date of May 15, 2024 and is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between...
This federal contract award, valued at $3,634.52, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 20 mg capsules, a medication commonly used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order (DO) under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This federal contract award, valued at $1,490.50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $11,860.62, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Vyvanse 50 mg capsules, a specialty medication used to treat attention-deficit/hyperactivity disorder (ADHD). The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This...
This federal contract award, valued at $23,317.81, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,638.64 firm fixed-price delivery order is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $3,193.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of Vyvanse 20 mg capsules, a drug used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a period of performance through December 26, 2024 and is a Firm Fixed Price contract type. This award is part of a larger Indefinite...
This federal contract award, valued at $33,989.86, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which is valued at...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FUPM8
    Delivery Order

This federal contract award, valued at $3,851.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 50 mg capsules, a prescription medication used to treat attention-deficit/hyperactivity disorder (ADHD).

The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 4/16/25, 6:09 PM